CoChat
Sign Up
Cited by 358

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Biomarkers of Parkinson’s disease: Present and future

Miller, Diane B., O’Callaghan, James P.·2015·Metabolism
DOI 10.1016/j.metabol.2014.10.030PMC PMC4721253
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2014.10.030

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Protein biomarkers based on alpha-synuclein (SNCA) and dopamine (DA) metabolic products have yielded mixed results, do not reflect disease progression, and require an invasive lumbar puncture.

    “In addition, protein biomarkers, such as those based on alpha‐synuclein (SNCA) and dopamine (DA) metabolic products have yielded mixed results, do not reflect disease progression and require an invasive lumbar puncture. 6”

    From Validation of differentially expressed brain‐enriched microRNAs in the plasma of PD patients (2020) · cites this paper as [6]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. Sharma, 2013, Biomarkers in Parkinson’s disease (recent update), Neurochem Int, 63, 201, 10.1016/j.neuint.2013.06.005 · DOI
  2. Ferrer, 2012, Neurochemistry and the non-motor aspects of PD, Neurobiol Dis, 46, 508, 10.1016/j.nbd.2011.10.019 · DOI
  3. Mielke, 2014, A ‘bird’s eye’ view on the current status and potential benefits of blood biomarkers for Parkinson’s disease, Biomark Med, 8, 225, 10.2217/bmm.13.139 · DOI
  4. Truong, 2008, Management of non-motor symptoms in advanced Parkinson disease, J Neurol Sci, 266, 216, 10.1016/j.jns.2007.08.015 · DOI
  5. Arkadir, 2014, Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease, Neurology, 82, 1093, 10.1212/WNL.0000000000000243 · DOI
  6. Biomarkers Definitions Working Group, 2001, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Clin Pharmacol Ther, 69, 89, 10.1067/mcp.2001.113989 · DOI
  7. DeKosky, 2003, Looking backward to move forward: early detection of neurodegenerative disorders, Science, 302, 830, 10.1126/science.1090349 · DOI
  8. Scherzer, 2009, Searching for biomarkers of Parkinson’s disease, Biomark Med, 3, 113, 10.2217/bmm.09.10 · DOI
  9. Fahn, 2005, Does levodopa slow or hasten the rate of progression of Parkinson’s disease?, J Neurol, 252, IV37
  10. Berg, 2013, Chang the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities, Lancet Neurol, 12, 514, 10.1016/S1474-4422(13)70047-4 · DOI
  11. Berg, 2014, Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease, Mov Disord, 29, 454, 10.1002/mds.25844 · DOI
  12. Bhidayasiri, 2013, Different diagnostic criteria for Parkinson disease: what are the pitfalls?, J Neural Transm, 120, 619, 10.1007/s00702-013-1007-z · DOI
  13. Lees, 2009, Parkinson’s disease, Lancet, 373, 2055, 10.1016/S0140-6736(09)60492-X · DOI · Paper page
  14. Deutch, 2013, Parkinson’s disease redefined, Lancet Neurol, 12, 422, 10.1016/S1474-4422(13)70052-8 · DOI
  15. Saracchi, 2014, Emerging candidate biomarkers for Parkinson’s disease: a review, 5, 27
  16. Schlossmacher, 2010, Biomarker research in Parkinson’s disease: objective measures needed for patient stratification in future cause-directed trials, Biomark Med, 4, 647, 10.2217/bmm.10.93 · DOI
  17. Streffer, 2012, Prerequisites to launch neuroprotective trials in Parkinson’s disease: an industry perspective, Mov Disord, 27, 651, 10.1002/mds.25017 · DOI
  18. Parnetti, 2013, Cerebrospinal fluid biomarkers in Parkinson disease, Nat Rev Neurol, 9, 131, 10.1038/nrneurol.2013.10 · DOI · Paper page
  19. Mohammadi, 2013, The Harvard Biomarker Study’s big plan, Lancet Neurol, 12, 739, 10.1016/S1474-4422(13)70155-8 · DOI
  20. Marek, 2011, The Paarkinson Progression Marker Initiative (PPMI), Prog Neurobiol, 95, 629, 10.1016/j.pneurobio.2011.09.005 · DOI
  21. Van Dijk, 2010, Diagnostic cerebrospinal fluid biomarkers for Parkinson’s disease: a pathogenetically based approach, Neurobiol Dis, 39, 229, 10.1016/j.nbd.2010.04.020 · DOI
  22. Yadav, 2012, Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson’s disease pathogenesis, Mol Neurobiol, 46, 495, 10.1007/s12035-012-8291-8 · DOI
  23. AIDakheel, 2014, Pathogenesis-targeted, disease-modifying therapies in Parkinson disease, Neurotherapeutics, 11, 6, 10.1007/s13311-013-0218-1 · DOI
  24. Hart, 2009, Neuroprotection trials in Parkinson’s disease: systematic review, Mov Disord, 24, 647, 10.1002/mds.22432 · DOI
  25. Lang, 2013, Trial designs used to study neuroprotective therapy in Parkinson’s disease, Mov Disord, 28, 86, 10.1002/mds.24997 · DOI
  26. Alonso-Navarro, 2014, Genomic and pharmacogenomic biomarkers of Parkinson’s disease, Curr Drug Metab, 15, 129, 10.2174/138920021502140327175404 · DOI
  27. Klein, 2012, Genetics of Parkinson’s disease, Cold Spring Harb Perspect Med, 2, a008888, 10.1101/cshperspect.a008888 · DOI
  28. Scholz, 2012, Genomics and bioinformatics of Parkinson’s disease, Cold Spring Harb Perspect Med, 2, a009449, 10.1101/cshperspect.a009449 · DOI
  29. Gasser, 2009, Genomic and proteomic biomarkers for Parkinson disease, Neurology, 72, S27
  30. Nyhlen, 2010, Problems associated with fluid biomarkers for Parkinson’s disease, Biomark Med, 4, 671, 10.2217/bmm.10.84 · DOI
  31. Adler, 2014, Submandibular gland needle biopsy for the diagnosis of Parkinson disease, Neurology, 82, 858, 10.1212/WNL.0000000000000204 · DOI
  32. Eller, 2011, α-Synuclein in Parkinson disease and other neurodegenerative disorders, Clin Chem Lab Med, 49, 403, 10.1515/CCLM.2011.077 · DOI
  33. Gelpi, 2013, Multiple organ involvement by alpha-synuclein pathology in Lewy Body disorders, Mov Disord, 00, 1
  34. Visanji, 2014, Alimentary, my dear Watson? The challenges of enteric α- synuclein as a Parkinson’s disease biomarker, Mov Disord, 29, 444, 10.1002/mds.25789 · DOI
  35. Wang, 2013, α-Synuclein in cutaneous autonomic nerves, Neurology, 81, 1604, 10.1212/WNL.0b013e3182a9f449 · DOI
  36. del Campo, 2012, Recommendations to standarize preanalyticl confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update, Biomark Med, 6, 419, 10.2217/bmm.12.46 · DOI · Paper page
  37. Mellick, 2010, Exploiting the potential of molecular profiling in Parkinson’s disease: current practice and future probabilities, Expert Rev Mol Diagn, 10, 1035, 10.1586/erm.10.86 · DOI
  38. Berg, 2008, Transcranial sonography in movement disorders, Lancet Neurol, 7, 1044, 10.1016/S1474-4422(08)70239-4 · DOI
  39. Gaig, 2009, When does Parkinson’s disease begin?, Mov Disord, 24, S656
  40. Tuite, 2013, Magnetic resonance imaging (MRI) in Parkinson’s disease, J Alzheimers Dis Res, S1, 001
  41. Poewe, 2012, Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson’s disease, Expert Rev Neurother, 12, 911, 10.1586/ern.12.75 · DOI
  42. Shao, 2014, Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and Parkinson’s disease using anatomic likelihood estimation, Front Hum Neurosci, 8, 63, 10.3389/fnhum.2014.00063 · DOI
  43. Berg, 2012, Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies, Mov Disord, 27, 656, 10.1002/mds.24985 · DOI
  44. Lerche, 2014, Mild parkinsonian signs in the elderly — is there an association with PD? Crossectional findings in 992 individuals, PLoS ONE, 9, e92878, 10.1371/journal.pone.0092878 · DOI
  45. Liepelt-Scarfone, 2013, Evaluation of progression markers in the premotor phase of Parkinson’s disease: the progression markers in the premotor phase study, Neuroepidemiology, 41, 174, 10.1159/000353560 · DOI
  46. Noyce, 2013, PREDICT-PD: identifying risk of Parkinson’s disease in the community: methods and baseline results, J Neurol Neurosurg Psychiatry, 1
  47. Garbayo, 2013, Drug development in Parkinson’s disease: from emerging molecules to innovative drug delivery systems, Maturitas, 76, 272, 10.1016/j.maturitas.2013.05.019 · DOI
  48. Schneeberger, 2012, Vaccination for Parkinson’s disease, Parkinsonism Relat Disord, 18, S11, 10.1016/S1353-8020(11)70006-2 · DOI
  49. Valera, 2013, Immunotherapy for neurodegenerative diseases: focus on a-synucleinopathies, Pharmacol Ther, 138, 311, 10.1016/j.pharmthera.2013.01.013 · DOI · Paper page
  50. Devic, 2011, Salivary a-synuclein and DJ-1: potential biomarkers for Parkinson’s disease, Brain, 134, e178, 10.1093/brain/awr015 · DOI
  51. Bogdanov, 2008, Metabolomic profiling to develop blood biomarkers for Parkinson’s disease, Brain, 131, 389, 10.1093/brain/awm304 · DOI
  52. Burgos, 2014, Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology, PLoS ONE, 9, e94839, 10.1371/journal.pone.0094839 · DOI · Paper page
  53. DeKosky, 2014, Environmental exposures and the risk for Alzheimer disease, JAMA Neurol, 71, 273, 10.1001/jamaneurol.2013.6031 · DOI

Cited by

Sorted by citations

Metadata

Authors
Miller, D. B., & O’Callaghan, J. P.
Venue
Metabolism
Publisher
Elsevier BV
Published
2015-03
Volume
64
Issue
3
Pages
S40-S46
ISSN
0026-0495
DOI
10.1016/j.metabol.2014.10.030
PMC
PMC4721253
Cited by
358
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review